Literature DB >> 33546206

Socioeconomic Factors and Survival of Multiple Myeloma Patients.

Kamal Chamoun1, Amin Firoozmand1, Paolo Caimi1, Pingfu Fu2, Shufen Cao2, Folashade Otegbeye1, Leland Metheny1, Seema Patel1, Stanton L Gerson1, Kirsten Boughan1, Marcos De Lima1, Ehsan Malek1.   

Abstract

BACKGROUND: Outcome of Multiple Myeloma (MM) patients has improved as the result of the introduction of novel medications and use of autologous hematopoietic cell transplantation. However, this improvement comes at the expense of increased financial burden. It is largely unknown if socioeconomic factors influence MM survival.
METHODS: We used the National Cancer Database, a database that houses data on 70% of cancer patients in the US, to evaluate the effect of socioeconomic factors on the survival of 117,926 MM patients diagnosed between 2005 and 2014.
RESULTS: Patients aged ≥65 years who were privately insured lived longer than patients with Medicare (42 months vs. 31 months, respectively, p < 0.0001). Treatment in academic institutions led to better survival (HR: 1.49, 95% CI: 1.39, 1.59). Younger age, fewer comorbidities, treatment in academic centers, and living in a higher median income area were significantly associated with improved survival. After adjusting for confounders, survival of Medicare patients was similar to those with private insurance. However, the hazard of death remained higher for patients with Medicaid (HR: 1.59, 95% CI: 1.36, 1.87) or without insurance (HR: 1.62, 95% CI: 1.32, 1.99), compared to privately insured patients.
CONCLUSION: Economic factors and treatment facility type play an important role in the survival of MM patients.

Entities:  

Keywords:  autologous stem cell transplant (ASCT); multiple myeloma (MM); overall survival (OS)

Year:  2021        PMID: 33546206      PMCID: PMC7913279          DOI: 10.3390/cancers13040590

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.575


  30 in total

1.  Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.

Authors:  Sonya Blesser Streeter; Lee Schwartzberg; Nadia Husain; Michael Johnsrud
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.

Authors:  Nathanael R Fillmore; Sarvari V Yellapragada; Chizoba Ifeorah; Ansh Mehta; Diana Cirstea; Paul S White; Gustavo Rivero; Andrew Zimolzak; Saiju Pyarajan; Nhan Do; Mary Brophy; Nikhil C Munshi
Journal:  Blood       Date:  2019-04-19       Impact factor: 22.113

3.  The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system.

Authors:  Brian G M Durie
Journal:  Eur J Cancer       Date:  2006-06-13       Impact factor: 9.162

4.  Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.

Authors:  Ehsan Malek; Vinita Gupta; Richard Creger; Paolo Caimi; Anant Vatsayan; Fahrettin Covut; Qaiser Bashir; Richard Champlin; Ruby Delgado; Gabriela Rondon; Brenda Cooper; Marcos de Lima; Hillard M Lazarus; Muzaffar Qazilbash
Journal:  Leuk Lymphoma       Date:  2018-01-02

5.  Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study.

Authors:  Scott F Huntington; Brendan M Weiss; Dan T Vogl; Adam D Cohen; Alfred L Garfall; Patricia A Mangan; Jalpa A Doshi; Edward A Stadtmauer
Journal:  Lancet Haematol       Date:  2015-09-17       Impact factor: 18.959

6.  The impact of health insurance status on the survival of patients with head and neck cancer.

Authors:  Joseph Kwok; Scott M Langevin; Athanassios Argiris; Jennifer R Grandis; William E Gooding; Emanuela Taioli
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

7.  The impact of health insurance status on stage at diagnosis of oropharyngeal cancer.

Authors:  Amy Y Chen; Nicole M Schrag; Michael T Halpern; Elizabeth M Ward
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

8.  Insurance status, comorbidity level, and survival among colorectal cancer patients age 18 to 64 years in the National Cancer Data Base from 2003 to 2005.

Authors:  Anthony S Robbins; Alexandre L Pavluck; Stacey A Fedewa; Amy Y Chen; Elizabeth M Ward
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

9.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

10.  Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.

Authors:  Sikander Ailawadhi; Ryan D Frank; Pooja Advani; Abhisek Swaika; M'hamed Temkit; Richa Menghani; Mayank Sharma; Zahara Meghji; Shumail Paulus; Nandita Khera; Shahrukh K Hashmi; Aneel Paulus; Tanya S Kakar; David O Hodge; Dorin T Colibaseanu; Michael R Vizzini; Vivek Roy; Gerardo Colon-Otero; Asher A Chanan-Khan
Journal:  Cancer Med       Date:  2017-11-03       Impact factor: 4.452

View more
  3 in total

1.  Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study.

Authors:  Jing Dong; Zhuping Garacci; Christopher Staffi Buradagunta; Anita D'Souza; Meera Mohan; Ashley Cunningham; Siegfried Janz; Binod Dhakal; Aaron P Thrift; Parameswaran Hari
Journal:  Blood Cancer J       Date:  2022-02-24       Impact factor: 9.812

2.  Autologous stem cell transplantation in an older adult population.

Authors:  Kateryna Fedorov; Tanim Jain; Kith Pradhan; Jennat Mustafa; Amanda Lombardo; Fariha Khatun; Felisha Joseph; Kailyn Gillick; Anjali Naik; Richard Elkind; Karen Fehn; Alyssa De Castro; Roy Browne; Michelly Abreu; Donika Binakaj; Monika Paroder; Carlo Palesi; Kira Gritsman; R Alejandro Sica; Noah Kornblum; Aditi Shastri; Ioannis Mantzaris; Nishi Shah; Amit Verma; Ira Braunschweig; Mendel Goldfinger
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

3.  Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations.

Authors:  Jiaxuan Xu; Peipei Xu; Qiaoyan Han; Jingjing Sun; Bing Chen; Xiaoqing Dong
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.